The impact of clinical phenotypes of coronary artery disease on outcomes in patients with atrial fibrillation: A post-hoc analysis of GLORIA-AF registry

The impact of clinical phenotypes of coronary artery disease on outcomes in patients with atrial fibrillation: A post-hoc analysis of GLORIA-AF registry

Coronary artery disease (CAD) and atrial fibrillation (AF) often coexist, but the impact of clinical phenotypes of CAD on outcomes in AF patients in the non-vitamin K antagonist oral anticoagulant drugs (NOACs) era is less well understood. This was a post-hoc of the GLORIA-AF registry, a global, mul...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of clinical investigation 2025-01, p.e14378
Hauptverfasser: Huang, Bi, Liu, Yang, Lam, Ho Man, Ishiguchi, Hironori, Chao, Tze-Fan, Huisman, Menno V, Lip, Gregory Y H
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page e14378
container_title European journal of clinical investigation
container_volume
creator Huang, Bi
Liu, Yang
Lam, Ho Man
Ishiguchi, Hironori
Chao, Tze-Fan
Huisman, Menno V
Lip, Gregory Y H
description Coronary artery disease (CAD) and atrial fibrillation (AF) often coexist, but the impact of clinical phenotypes of CAD on outcomes in AF patients in the non-vitamin K antagonist oral anticoagulant drugs (NOACs) era is less well understood. This was a post-hoc of the GLORIA-AF registry, a global, multicenter, prospective AF registry study. Patients were divided into three groups: prior history of myocardial infarction (MI)/unstable angina group (Group 1); stable angina group (Group 2); and a control group without stable angina or history of MI/unstable angina. The primary endpoint was the composite of all-cause death or stroke, and the safety endpoint was major bleeding. A total of 24,827 patients were included in this analysis (median age was 71 (IQR, 64-78) years; 55% male) and 5394 (21.7%) had CAD. During a follow-up of 2 years, the incidence of the primary endpoint was 5.99 (95% CI, 5.33, 6.71) per 100 patient-years in Group 1, 4.04 (95% CI, 3.55, 4.70) per 100 patient-years in Group 2, and 2.79 (95% CI, 2.62, 2.96) per 100 patient-years in the control group (p 
doi_str_mv 10.1111/eci.14378
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3155359318</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3155359318</sourcerecordid><originalsourceid>FETCH-LOGICAL-c175t-c60501f697758b985a9f899dbcfc94e3f5098334a9b973191ab33a10c25f7c0f3</originalsourceid><addsrcrecordid>eNo9kctOwzAQRS0EglJY8APIS1ik2Jk6idlFFS-pUiVU1pHj2sQosYPtCvVP-FxMeczmSjNHd0ZzEbqgZEZT3ShpZnQOZXWAJhQKluVQ5IdoQgidZzkv8xN0GsIbIaSikB-jE-AVYQWQCfpcdwqbYRQyYqex7I01UvR47JR1cTeqsG8776zwOyx8VEk2JigRFHYWu22UbkiYsXgU0SgbA_4wscMiepOctGm96fs0cvYW13h0IWadk1hY0e-C2S94WK6en-qsvsdevZoQ_e4MHWnRB3X-q1P0cn-3Xjxmy9XD06JeZpKWLGayIIxQXfCyZFXLKya4rjjftFJLPlegGeEVwFzwlpdAORUtgKBE5kyXkmiYoqsf39G7960KsRlMkCodbJXbhgYoY8A40Cqh1z-o9C4Er3QzejOktzSUNN9BNCmIZh9EYi9_bbftoDb_5N_n4Qt56oUM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3155359318</pqid></control><display><type>article</type><title>The impact of clinical phenotypes of coronary artery disease on outcomes in patients with atrial fibrillation: A post-hoc analysis of GLORIA-AF registry</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Huang, Bi ; Liu, Yang ; Lam, Ho Man ; Ishiguchi, Hironori ; Chao, Tze-Fan ; Huisman, Menno V ; Lip, Gregory Y H</creator><creatorcontrib>Huang, Bi ; Liu, Yang ; Lam, Ho Man ; Ishiguchi, Hironori ; Chao, Tze-Fan ; Huisman, Menno V ; Lip, Gregory Y H ; GLORIA‐AF Investigators ; the GLORIA‐AF Investigators</creatorcontrib><description>Coronary artery disease (CAD) and atrial fibrillation (AF) often coexist, but the impact of clinical phenotypes of CAD on outcomes in AF patients in the non-vitamin K antagonist oral anticoagulant drugs (NOACs) era is less well understood. This was a post-hoc of the GLORIA-AF registry, a global, multicenter, prospective AF registry study. Patients were divided into three groups: prior history of myocardial infarction (MI)/unstable angina group (Group 1); stable angina group (Group 2); and a control group without stable angina or history of MI/unstable angina. The primary endpoint was the composite of all-cause death or stroke, and the safety endpoint was major bleeding. A total of 24,827 patients were included in this analysis (median age was 71 (IQR, 64-78) years; 55% male) and 5394 (21.7%) had CAD. During a follow-up of 2 years, the incidence of the primary endpoint was 5.99 (95% CI, 5.33, 6.71) per 100 patient-years in Group 1, 4.04 (95% CI, 3.55, 4.70) per 100 patient-years in Group 2, and 2.79 (95% CI, 2.62, 2.96) per 100 patient-years in the control group (p &lt; .001). Compared the control group, the adjusted hazard ratio of the primary composite endpoint in Groups 1 and 2 were 1.58 (95% CI, 1.37, 1.83, p &lt; .001) and 1.22 (95% CI, 1.04, 1.43, p = .012), respectively. Among anticoagulated patients with AF and CAD, NOACs were associated with a reduced risk of the primary composite endpoint and major bleeding, compared with vitamin K antagonists (VKA). CAD was prevalent in patients with AF, and clinical phenotypes of CAD influenced outcomes in patients with AF, with a history of MI/unstable angina being associated with a significantly increased risk of CV events, compared to stable angina. NOACs were superior to VKA in terms of the effectiveness and safety outcomes in patients with AF and concomitant CAD.</description><identifier>ISSN: 0014-2972</identifier><identifier>ISSN: 1365-2362</identifier><identifier>EISSN: 1365-2362</identifier><identifier>DOI: 10.1111/eci.14378</identifier><identifier>PMID: 39805630</identifier><language>eng</language><publisher>England</publisher><ispartof>European journal of clinical investigation, 2025-01, p.e14378</ispartof><rights>2025 The Author(s). European Journal of Clinical Investigation published by John Wiley &amp; Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c175t-c60501f697758b985a9f899dbcfc94e3f5098334a9b973191ab33a10c25f7c0f3</cites><orcidid>0000-0003-4597-7862 ; 0000-0002-6587-3094 ; 0000-0003-2147-0995 ; 0000-0002-1763-8452</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39805630$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huang, Bi</creatorcontrib><creatorcontrib>Liu, Yang</creatorcontrib><creatorcontrib>Lam, Ho Man</creatorcontrib><creatorcontrib>Ishiguchi, Hironori</creatorcontrib><creatorcontrib>Chao, Tze-Fan</creatorcontrib><creatorcontrib>Huisman, Menno V</creatorcontrib><creatorcontrib>Lip, Gregory Y H</creatorcontrib><creatorcontrib>GLORIA‐AF Investigators</creatorcontrib><creatorcontrib>the GLORIA‐AF Investigators</creatorcontrib><title>The impact of clinical phenotypes of coronary artery disease on outcomes in patients with atrial fibrillation: A post-hoc analysis of GLORIA-AF registry</title><title>European journal of clinical investigation</title><addtitle>Eur J Clin Invest</addtitle><description>Coronary artery disease (CAD) and atrial fibrillation (AF) often coexist, but the impact of clinical phenotypes of CAD on outcomes in AF patients in the non-vitamin K antagonist oral anticoagulant drugs (NOACs) era is less well understood. This was a post-hoc of the GLORIA-AF registry, a global, multicenter, prospective AF registry study. Patients were divided into three groups: prior history of myocardial infarction (MI)/unstable angina group (Group 1); stable angina group (Group 2); and a control group without stable angina or history of MI/unstable angina. The primary endpoint was the composite of all-cause death or stroke, and the safety endpoint was major bleeding. A total of 24,827 patients were included in this analysis (median age was 71 (IQR, 64-78) years; 55% male) and 5394 (21.7%) had CAD. During a follow-up of 2 years, the incidence of the primary endpoint was 5.99 (95% CI, 5.33, 6.71) per 100 patient-years in Group 1, 4.04 (95% CI, 3.55, 4.70) per 100 patient-years in Group 2, and 2.79 (95% CI, 2.62, 2.96) per 100 patient-years in the control group (p &lt; .001). Compared the control group, the adjusted hazard ratio of the primary composite endpoint in Groups 1 and 2 were 1.58 (95% CI, 1.37, 1.83, p &lt; .001) and 1.22 (95% CI, 1.04, 1.43, p = .012), respectively. Among anticoagulated patients with AF and CAD, NOACs were associated with a reduced risk of the primary composite endpoint and major bleeding, compared with vitamin K antagonists (VKA). CAD was prevalent in patients with AF, and clinical phenotypes of CAD influenced outcomes in patients with AF, with a history of MI/unstable angina being associated with a significantly increased risk of CV events, compared to stable angina. NOACs were superior to VKA in terms of the effectiveness and safety outcomes in patients with AF and concomitant CAD.</description><issn>0014-2972</issn><issn>1365-2362</issn><issn>1365-2362</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><recordid>eNo9kctOwzAQRS0EglJY8APIS1ik2Jk6idlFFS-pUiVU1pHj2sQosYPtCvVP-FxMeczmSjNHd0ZzEbqgZEZT3ShpZnQOZXWAJhQKluVQ5IdoQgidZzkv8xN0GsIbIaSikB-jE-AVYQWQCfpcdwqbYRQyYqex7I01UvR47JR1cTeqsG8776zwOyx8VEk2JigRFHYWu22UbkiYsXgU0SgbA_4wscMiepOctGm96fs0cvYW13h0IWadk1hY0e-C2S94WK6en-qsvsdevZoQ_e4MHWnRB3X-q1P0cn-3Xjxmy9XD06JeZpKWLGayIIxQXfCyZFXLKya4rjjftFJLPlegGeEVwFzwlpdAORUtgKBE5kyXkmiYoqsf39G7960KsRlMkCodbJXbhgYoY8A40Cqh1z-o9C4Er3QzejOktzSUNN9BNCmIZh9EYi9_bbftoDb_5N_n4Qt56oUM</recordid><startdate>20250113</startdate><enddate>20250113</enddate><creator>Huang, Bi</creator><creator>Liu, Yang</creator><creator>Lam, Ho Man</creator><creator>Ishiguchi, Hironori</creator><creator>Chao, Tze-Fan</creator><creator>Huisman, Menno V</creator><creator>Lip, Gregory Y H</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4597-7862</orcidid><orcidid>https://orcid.org/0000-0002-6587-3094</orcidid><orcidid>https://orcid.org/0000-0003-2147-0995</orcidid><orcidid>https://orcid.org/0000-0002-1763-8452</orcidid></search><sort><creationdate>20250113</creationdate><title>The impact of clinical phenotypes of coronary artery disease on outcomes in patients with atrial fibrillation: A post-hoc analysis of GLORIA-AF registry</title><author>Huang, Bi ; Liu, Yang ; Lam, Ho Man ; Ishiguchi, Hironori ; Chao, Tze-Fan ; Huisman, Menno V ; Lip, Gregory Y H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c175t-c60501f697758b985a9f899dbcfc94e3f5098334a9b973191ab33a10c25f7c0f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huang, Bi</creatorcontrib><creatorcontrib>Liu, Yang</creatorcontrib><creatorcontrib>Lam, Ho Man</creatorcontrib><creatorcontrib>Ishiguchi, Hironori</creatorcontrib><creatorcontrib>Chao, Tze-Fan</creatorcontrib><creatorcontrib>Huisman, Menno V</creatorcontrib><creatorcontrib>Lip, Gregory Y H</creatorcontrib><creatorcontrib>GLORIA‐AF Investigators</creatorcontrib><creatorcontrib>the GLORIA‐AF Investigators</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Bi</au><au>Liu, Yang</au><au>Lam, Ho Man</au><au>Ishiguchi, Hironori</au><au>Chao, Tze-Fan</au><au>Huisman, Menno V</au><au>Lip, Gregory Y H</au><aucorp>GLORIA‐AF Investigators</aucorp><aucorp>the GLORIA‐AF Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The impact of clinical phenotypes of coronary artery disease on outcomes in patients with atrial fibrillation: A post-hoc analysis of GLORIA-AF registry</atitle><jtitle>European journal of clinical investigation</jtitle><addtitle>Eur J Clin Invest</addtitle><date>2025-01-13</date><risdate>2025</risdate><spage>e14378</spage><pages>e14378-</pages><issn>0014-2972</issn><issn>1365-2362</issn><eissn>1365-2362</eissn><abstract>Coronary artery disease (CAD) and atrial fibrillation (AF) often coexist, but the impact of clinical phenotypes of CAD on outcomes in AF patients in the non-vitamin K antagonist oral anticoagulant drugs (NOACs) era is less well understood. This was a post-hoc of the GLORIA-AF registry, a global, multicenter, prospective AF registry study. Patients were divided into three groups: prior history of myocardial infarction (MI)/unstable angina group (Group 1); stable angina group (Group 2); and a control group without stable angina or history of MI/unstable angina. The primary endpoint was the composite of all-cause death or stroke, and the safety endpoint was major bleeding. A total of 24,827 patients were included in this analysis (median age was 71 (IQR, 64-78) years; 55% male) and 5394 (21.7%) had CAD. During a follow-up of 2 years, the incidence of the primary endpoint was 5.99 (95% CI, 5.33, 6.71) per 100 patient-years in Group 1, 4.04 (95% CI, 3.55, 4.70) per 100 patient-years in Group 2, and 2.79 (95% CI, 2.62, 2.96) per 100 patient-years in the control group (p &lt; .001). Compared the control group, the adjusted hazard ratio of the primary composite endpoint in Groups 1 and 2 were 1.58 (95% CI, 1.37, 1.83, p &lt; .001) and 1.22 (95% CI, 1.04, 1.43, p = .012), respectively. Among anticoagulated patients with AF and CAD, NOACs were associated with a reduced risk of the primary composite endpoint and major bleeding, compared with vitamin K antagonists (VKA). CAD was prevalent in patients with AF, and clinical phenotypes of CAD influenced outcomes in patients with AF, with a history of MI/unstable angina being associated with a significantly increased risk of CV events, compared to stable angina. NOACs were superior to VKA in terms of the effectiveness and safety outcomes in patients with AF and concomitant CAD.</abstract><cop>England</cop><pmid>39805630</pmid><doi>10.1111/eci.14378</doi><orcidid>https://orcid.org/0000-0003-4597-7862</orcidid><orcidid>https://orcid.org/0000-0002-6587-3094</orcidid><orcidid>https://orcid.org/0000-0003-2147-0995</orcidid><orcidid>https://orcid.org/0000-0002-1763-8452</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0014-2972
ispartof European journal of clinical investigation, 2025-01, p.e14378
issn 0014-2972
1365-2362
1365-2362
language eng
recordid cdi_proquest_miscellaneous_3155359318
source Wiley Online Library Journals Frontfile Complete
title The impact of clinical phenotypes of coronary artery disease on outcomes in patients with atrial fibrillation: A post-hoc analysis of GLORIA-AF registry
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T23%3A23%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20impact%20of%20clinical%20phenotypes%20of%20coronary%20artery%20disease%20on%20outcomes%20in%20patients%20with%20atrial%20fibrillation:%20A%20post-hoc%20analysis%20of%20GLORIA-AF%20registry&rft.jtitle=European%20journal%20of%20clinical%20investigation&rft.au=Huang,%20Bi&rft.aucorp=GLORIA%E2%80%90AF%20Investigators&rft.date=2025-01-13&rft.spage=e14378&rft.pages=e14378-&rft.issn=0014-2972&rft.eissn=1365-2362&rft_id=info:doi/10.1111/eci.14378&rft_dat=%3Cproquest_cross%3E3155359318%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3155359318&rft_id=info:pmid/39805630&rfr_iscdi=true